Author Archives: Scalper1

Will GLD Resume Its Decline?

The market remains on fence on the timing of the Fed’s rate hike. SPDR Gold Trust benefits from economic uncertainty but not from low inflation. The Fed still expects inflation will reach its target in the coming years. A strong non-farm payroll report could further push down the price of GLD. Even though shares of SPDR Gold Trust (NYSEARCA: GLD ) are up for August , they are still down for the year. The debate over the Federal Reserve’s rate hike continues. The devaluation of the Chinese yuan along with low inflation and the strong U.S. dollar reduce the odds of a rate hike in September. But the Fed keeps us guessing. Nonetheless, a stronger than expected non-farm payroll report could bring back up the probability of a September hike and drag back down the price of GLD. Let’s see the recent developments in the market and their relation to GLD. The market still doesn’t know when the Fed will be ready to hit liftoff. And although the implied probabilities for a September rate hike are still very low – the odds are only 28% in September and 56% in December, the market could still raise these odds again if the upcoming non-farm payroll report exceeds the market’s expectations. Currently, the market expects a gain of around 220,000 jobs; if the actual number comes at over 250,000 this may be enough to rekindle the possibility of a rate hike later this month. Back in July, the NFP report showed a gain of 215,000, slightly below expectations, which still led to a rise in the price of GLD. When it comes to the September rate hike, even Federal Reserve Vice Chair Stanley Fischer , in a recent interview, still refrained from voicing his opinion about the September meeting and kept the possibility of a hike on the table. He was also optimistic in Jackson Hole and thinks inflation will pick up: “Given the apparent stability of inflation expectations, there is good reason to believe that inflation will move higher as the forces holding down inflation dissipate further.” If this is the case, it will be harder for the Fed to reach its goal of 2% as rates start to rise again. Also, inflation aren’t, for now, rising. Moreover, the ongoing descent in the core CPI may have also contributed to the weakness of gold in the past couple of years. The chart below presents the price of gold and annual percent changes in core PCE between 2011 and 2015. (click to enlarge) Source: FRED The combination of a stronger dollar, which is likely to further strengthen as the Fed begins normalization, along with the low price environment, driven, in part, by falling commodities prices, isn’t expected to help gold or the price of GLD to bounce back from its recent fall. It’s also worth noting, a point made on CNBC , that the current long-term yields are still low – the 10-year Treasury bond yields are around 2.2%. Back when the Fed started to raise rates, yields were much higher – the spread between the federal funds rate and the 10-year note was closer to 4%. Thus, the market conditions, at least from the bond market, aren’t best for a rate hike. I think it’s not likely that the Fed will raise rates – for the same reasons everyone states including China, low inflation and yields, global economic uncertainty, strong U.S. dollar and more – any time soon. But we should also remember the Fed is purposefully avoiding from giving clearer guidance and keeping us guessing: It’s trying to test the waters and see the market’s reactions. So far, the growth in the U.S., which was very strong in Q2, could still change course. The labor market is improving but still has room for improvement especially when it comes to wages. And most importantly, inflation is low and higher rates won’t bring it any faster to the Fed’s target. For GLD, low inflation and the strong U.S. dollar will drag its shares down. Conversely, economic uncertainty could play in favor for its price – as was the case back in mid-August. Thus, over the short term, we could still see modest gains in the price of GLD, but as long as the Fed heads towards normalization – if not in September then in December or the beginning of 2016 – the U.S. dollar is, for the most part, heading up, GLD is likely to resume its slow descent. For more please see: 3 Questions About Investing in Gold . Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Twitter Said Poised To Name New CEO, Shake Up Board

Twitter stock rose Monday after SunTrust Robinson Humphrey said the microblog could soon name a new CEO and shake up its board. Twitter stock this month for the first time sank below its IPO price of 26, as the company struggles to ignite user growth. But Twitter stock was up 5% in afternoon trading in the stock market today, above 28, as SunTrust analyst Robert Peck upgraded the stock to buy from neutral. User metrics have “stabilized,” Peck

Tracking The Sequoia Fund – Q2 2015 Update

Summary For the second quarter of 2015, the fund was up 1.96% versus 0.28% for the S&P 500. Top 10 holdings (65.5% of the fund): Valeant Pharmaceuticals, Berkshire Hathaway, TJX Companies, O’Reilly Automotive, Fastenal, MasterCard, Precision Castparts, Mohawk Industries, IDEXX Laboratories, and Google. During the second quarter, the fund cut its position in Qinetiq Group and Novozymes A/S and trimmed its third largest holding, TJX Companies. Since its inception on 7/15/1970, an investment in the Sequoia Fund (MUTF: SEQUX ) has returned 14.61% annually versus 10.88% for the S&P 500. The fund is noted for its long-term value investing style, portfolio concentration, and outperforming in down years. For more background on the fund, you can check out my original article here . The fund noted in the second quarter that it doesn’t know which way the market is going and trying to predict its direction is futile. The fund continues to look for market-leading companies that earn high returns on capital, boast strong balance sheets and self-fund their growth. The fund also likes to invest alongside motivated, ethical management teams. With over 15% of the fund in cash, the fund has plenty dry powder for when opportunities arise. Valeant Pharmaceuticals (NYSE: VRX ) continues to be the largest position in the fund by far, accounting for nearly 29% of the fund. If you’re interested in learning Sequoia’s thought process for owning the stock, check out the investor day presentation from May, you can find the link here . Valeant continues to keep busy on the acquisition front and recently acquired the “female Viagra,” a new FDA approved drug called Addyi. Here’s the fund activity for the second quarter of 2015. New Stakes: None Stake Disposals: Qinetiq Group ( OTCPK:QNTQY ) is a British multinational defense technology company. The fund acquired 23 million shares back in 2010 for a roughly 1% stake in the portfolio. The ADR traded between $6 and $8 at the time. The fund maintained its position through 2013. During the fourth quarter of 2014, the fund sold over 43% of its position. Prices ranged from $11.50 to $14.75. In the annual report, the fund noted how it has been disappointed in the results of its European companies, including Qinetiq. The selling continued in the first quarter of 2015. The fund sold 27% of its position, just over 3.5 million shares. Prices ranged from $11 to $12.50. The job was finished in the second quarter of 2015 as the fund disposed of its remaining 9.4 million shares while prices traded between $11.25 and $15.00. Novozymes A/S ( OTCPK:NVZMY ) produces and sells industrial enzymes, microorganisms, and biopolymers worldwide. The fund bought just over 2 million shares in the second quarter of 2012 when prices ranges from $25.50 to $29.50. The fund likes Novozymes for its industrial enzymes, animal nutrition, and corn ethanol enzymes businesses. It estimates the company has a dominant market share in industrial enzymes and a 60% market share in corn ethanol enzymes. It also likes that there are high barriers of entry for these businesses due to the time, expertise, and resources needed to produce its products and operate efficiently. In the first quarter of 2015, the fund sold 221k shares, or 10.7% of its position, when prices ranged from $40 to $50. The fund sold its remaining stake in the second quarter of 2015. Prices ranged from $45.50 to $49.50. Stake Increases: None Stake Decreases: Rolls Royce ( OTCPK:RYCEY ) designs, develops, manufactures, and services integrated power systems worldwide. The company is known for its expertise in making engines for wide-body jets. The fund has been in Rolls Royce since 2007. It built up the position to over 12 million shares by the end of 2008. Since then it’s held, save very minor selling. Despite continuing to hold, the fund is very concerned over the position. While it admires its jet engine business, it questions the board of directors’ recent decisions to diversify into marine engine and power generation businesses. It’s also concerned the company is abandoning its Total Care service contract selling model which was very successful under the former CEO. As for the current CEO, John Rishton, the fund says, “… in our meetings with him, has shown minimal awareness of the returns on capital his acquisitions have generated.” The fund was selling in the second quarter, trimming the position by 437k shares when prices traded between $13.75 and $16.00. The stock is now trading below $12. Perrigo Company (NYSE: PRGO ) is a developer and manufacturer of over-the-counter consumer goods and pharmaceutical products. The fund picked up just over a half million shares in the third quarter of 2010. The stock traded between $55 and $66.50. In April of this year Mylan N.V. (NASDAQ: MYL ) made an unsolicited $29 billion bid for Perrigo. At the same time, Teva (NYSE: TEVA ) made a $40 billion offer for Mylan. That eventually fell through. Mylan has since upped its bid for Perrigo to $33 billion and then again to nearly $36 billion. Mylan shareholders recently approved the transaction and the company will be taking the deal directly to Perrigo shareholders. We’ll see what happens. The fund trimmed its Perrigo position by about 13% during the second quarter. Prices traded between $183 and $215 after Mylan’s original offer. TJX Companies (NYSE: TJX ) is a discount apparel and home furnishing retailer operating under the T.J.Maxx, Marshalls and HomeGoods brands. The fund has been in TJX since 2000, when it held nearly 7.9 million shares. The position was built up to over 15 million shares by the end of 2002. The fund steadily decreased its position between 2003 and 2007, and by 2008, it was down to 4.9 million shares. The fund added significantly in 2011, increased the position size from 5.1 million to 10.2 million shares. Prices ranged from $21.50 to $32.69 in 2011. The fund still holds 10.2 million shares and the position makes up 7.88% of the portfolio. Three quarters ago, the fund sold approximately 400k shares, or 4% of the position. It sold another 1% of its position last quarter. And the selling accelerated in the second quarter as the fund sold over 3.1 million shares at prices between $64 and $70. TJX is still a top three holding for the fund, but its percentage of the portfolio has gone from 8% to 5%. Kept Steady: Omnicom (NYSE: OMC ) , Precision Castparts (NYSE: PCP ), Compagnie Financiere Richemont SA ( OTCPK:CFRUY ) , Constellation Software ( OTCPK:CNSWF ), O’Reilly Automotive (NASDAQ: ORLY ) , Jacobs Engineering (NYSE: JEC ) , Canadian Natural Resources (NYSE: CNQ ) , Sirona Dental Systems (NASDAQ: SIRO ) , Berkshire Hathaway (NYSE: BRK.A ) (NYSE: BRK.B ) , Danaher (NYSE: DHR ) , EMCOR Group (NYSE: EME ) , Trimble Navigation (NASDAQ: TRMB ) , Mohawk Industries (NYSE: MHK ) , Expeditors International (NASDAQ: EXPD ) , Valeant Pharmaceuticals (VRX) , West Pharmaceuticals (NYSE: WST ) , Zoetis (NYSE: ZTS ) , Fastenal Company (NASDAQ: FAST ) , Praxair (NYSE: PX ) , IMI plc ( OTCQX:IMIAY ) , MasterCard (NYSE: MA ) , Brown & Brown (NYSE: BRO ) , Google (NASDAQ: GOOGL ) (NASDAQ: GOOG ) , Goldman Sachs (NYSE: GS ) , International Business Machines (NYSE: IBM ) , Waters Corporation (NYSE: WAT ) , Admiral Group ( OTCPK:AMIGY ) , Hiscox Ltd. ( OTC:HCXLY ), Verisk Analytics (NASDAQ: VRSK ) , Costco Wholesale (NASDAQ: COST ) , Tiffany & Co. (NYSE: TIF ) , Wal-Mart (NYSE: WMT ) , Croda International ( OTCPK:COIHY ) , Cabela’s (NYSE: CAB ), and IDEXX Laboratories (NASDAQ: IDXX ) saw no changes from the first quarter of 2015 to second quarter of 2015. Here’s a snapshot of the activity from the first quarter of 2015 to the second quarter of 2015: (click to enlarge) Editor’s Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks. Disclosure: I am/we are long GOOGL, OMC, FAST, WMT. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.